Glaxo-Innoviva Triple Combo Inhaler Positive in Phase III
GlaxoSmithKline plc GSK and partner Innoviva, Inc. INVA announced that its once-daily single inhaler triple therapy - Trelegy Ellipta - met primary endpoint in a phase III IMPACT study, showing ... GSK and Innoviva Report Positive Headline Results from IMPACT Study Showing ... - Business Wire Theravance Biopharma Highlights Positive Headline Results from IMPACT Study of ... - Markets Insider
Story MomentumThis story impact on price volatility cannot be determined at this time. Please check this story after some time to allow current data to be analyzed.
Similar stores for Theravance
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
|Hide View All Next||Launch Financial Widgets|